Gilead, Carna BioSciences Form $470-Million Immuno-Oncology PactBy
Gilead Sciences and Carna BioSciences, a biopharmaceutical company developing kinase inhibitor drugs for oncology, autoimmune, and neurological diseases, have entered into a research and development collaboration to develop and commercialize small-molecule compounds in immuno-oncology in a deal worth up to $470 million.
Under the agreement, Gilead will license worldwide rights from Carna to develop and commercialize inhibitors against an undisclosed immune-oncology target. Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in potential milestone payments upon achievement of certain development and commercial milestones as well as receive royalties on future net sales.
Under the collaboration, Gilead will also have exclusive access to Carna’s proprietary lipid kinase drug discovery platform.